Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion System

Core Insights - Aurora Spine Corporation has received FDA 510(k) clearance for its AERO™ Facet Fusion System, marking a significant advancement in its product pipeline [1][5] Product Overview - The AERO MIS Facet Fusion System is a patent-pending device designed for minimally invasive treatment of facet joint-related pain or instability, applicable from spinal levels C2 to S1 [2] - The system can be utilized as a stand-alone procedure or in conjunction with larger spinal fusion surgeries [2] Clinical Application - AERO is intended for patients with mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies, promoting bone fusion while minimizing soft tissue disruption [3] - Initial surgeries using the AERO system are anticipated to commence in late Q3 2025, with leading spine surgeons participating in a clinical study to validate clinical outcomes and long-term benefits [4] Company Statements - The President and CEO of Aurora Spine expressed enthusiasm about the FDA clearance, highlighting the system's design for physicians treating facet joint issues and its potential as a growth driver for the company [5] - The Chief Technology Officer emphasized the thoughtful engineering behind the AERO system, reflecting the company's commitment to improving patient care through innovation [5] Company Background - Aurora Spine focuses on developing new solutions in the spinal implant market through proprietary, minimally invasive, and regenerative technologies aimed at enhancing surgical outcomes [6]